113 results about "Vitamin A Retinol" patented technology

Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and / or prevention of age-related macular degeneration and / or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

A composition is described comprising a vitamin D analog and a retinoid wherein: (a) the vitamin D analog is capable of binding a vitamin D receptor or being converted in vivo into a compound capable of binding a vitamin D receptor; and (b) the retinoid is selected from the group consisting of retinol in a concentration of at least about 1.0% and a retinoid characterized by having a substitution at the 4-position. Further, methods of treating disorders characterized by abnormal cell-proliferation and / or cell-differentiation are also described.

The invention relates to compounds and to the cosmetically acceptable salts thereof, which correspond to general formula (I), wherein: R1 represents H, —C(O)—R6, —SO2—R6 or —C(O)—XR6; R2 and R4, independent of one another, represent (CH2)n—NH2 or (CH2)3—NHC(NH)NH2; n equals 1 4; R3 represents linear or branched C1-C4 alkyl that is optionally substituted by hydroxy; R5 and R6, independent of one another, represent hydrogen, optionally substituted (C1-C24) alkyl, optionally substituted C2-C24 alkenyl, optionally substituted phenyl, optionally substituted phenyl-C1-C4 alkyl or 9-fluorenyl-methyl; X represents oxygen (—O—) or —NH—; or XR5 with X=O also represents the esters of a-tocopherol, tocotrienol or retinol, with the provision that R1 and R5 do not represent hydrogen and X does not represent oxygen at the same time. The invention also relates to the production of the compounds of general formula (I) and to a cosmetically active composition that contains at least one compound of formula (I).

A composition is described comprising a vitamin D analog and a retinoid, wherein: (a) the vitamin D analog is capable of binding a vitamin D receptor or being converted in vivo into a compound capable of binding a vitamin D receptor; and (b) the retinoid is selected from the group consisting of a compound capable of binding a retinoic acid receptor, retinol in a concentration of at least about 0.1% and a compound in a concentration of at least about 0.% capable of being converted in vivo into retinol. Further, methods of treating disorders characterized by abnormal cell-proliferation and / or cell-differentiation are also described.

Compounds that reduce serum retinol levels are used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods, compounds, and compositions to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions.

The objetive of the present invention was to enhance the skin whitening effects and blackening prevention effects and supply safe and stable topical agents for dermatological use. For that purpose 4-Hydroxyphenyl-alpha-D-glucopyranoside was combined with auxiliary agents such as ascorbic acid and its derivatives, crude drugs and its extracts, hydroxycarboxylic acid and its salts, oil soluble glycyrrhiza extract, gentian extract, phenol derivatives and their salts, placenta extract, kojic acid and its derivative, glucosamine and its derivatives, azelaic acid and its derivatives, retinol and its derivatives, pyridoxin and its derivatives, tocopherol and its derivatives, chitosan and its decomposition products, caffeic acid derivatives, hydroxycinnamate and its derivatives, Umbelliferae plant extracts, mycelial cultures and their extracts, plant leaves and their extracts.

An anti-aging composition is provided that contains high potency retinol along with anti-irritant properties. In particular, an anti-aging composition includes a base, from about 0.001% to 20.0 vol % retinol, at least one anti-irritant agent, at least one antioxidant, at least one anti-inflammatory agent, and a moisturizing complex. In one non-limiting illustration, the anti-aging composition contains about 1.0 vol % retinol, plantago lanceolata, hypericum perforatum leaf extract, phytosphingosine, leontopodium alpinum extract, glycyrriza glabra root extract, sambucus nigra flower extract, nordihydrognaiaretic acid, oleanolic acid, spiraea ulmaria flower extract, evodia rutaecarpa fruit extract, boswellia serrata extract, and additives.

A vaginal care composition which is introduced directly into the vagina in the form of an ovule, a cream or an ointment or with a tampon or which is brought into a position outside the vagina on a panty liner. The composition comprises viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s); vitamin A / retinol, and zinc.

There is provided a dietary or health supplement comprising an effective amount of a micronutrient selected from the group consisting of phosphate derivatives of tocopherol, ubiquinol, ascorbic acid, tocotrienol, retinol and mixtures thereof delivered with an acceptable carrier.

There is provided a dietary or health supplement comprising an effective amount of a micronutrient selected from the group consisting of phosphate derivatives of tocopherol, ubiquinol, ascorbic acid, tocotrienol, retinol and mixtures thereof delivered with an acceptable carrier.

An oil-in-water emulsion formulation containing hydroquinone and retinol, which comprises an oil-in-water emulsion containing free hydroquinone, hydroquinone entrapped in absorbent micro-agglomerates and / or impregnated in porous microparticles; and retinol-impregnated microparticles.

The present invention relates to compositions and methods for modulating retinol binding to retinol binding protein 4 (RBP4). In particular, the present invention provides compounds having Formula (1) or (2) (Formulae (1), (2)); wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, Y4 and m are as defined above.

Methods of producing a controlled release formulation for an active substance are disclosed, wherein the methods involve dispersing a discontinuous phase comprising an active substance into a continuous phase so as to form a two-phase liquid system comprising droplets of said discontinuous phase, and allowing nanoparticles provided to the two-phase liquid system to congregate at the phase interface to thereby coat the surface of the droplets in at least one layer of said nanoparticles. The methods utilise a concentration of a suitable electrolyte which enhances the nanoparticle congregation such that the coating of nanoparticles on the surface of the droplets presents a semi-permeable barrier to the active substance, or otherwise utilise a amount of the active substance that is greater than the solubility limit of that active substance in the discontinous phase. Formulations comprising vitamin A (retinol) as the active substance for dermal delivery are specifically exemplified.

The present invention concerns stabilized cosmetic material containing triple-encapsulated retinol. Unstable, fat-soluble retinol is stabilized firstly by addition into vesicles consisting of nonionic surface-active agent, cholesterol and cholesteryl ester. The firstly stabilized retinol(vesicle) is subsequently inserted into sphingosomes (a kind of multi lamellar liposome) consisting of lecithin and ceramide. Finally the double-encapsulated retinol (sphingosome) is inserted into lamellar liquid-crystal emulsifying base, thereby being triply encapsulated.

The invention discloses a method of simultaneously detecting contents of vitamin A (retinol) and vitamin E (alpha-tocopherol) in blood. The method comprises the following steps: (1) centrifuging a whole blood sample, and taking a supernatant to obtain serum or plasma for standby application; (2) calibrating a standard solution; (3) pretreating the sample; and (4) automatically putting 80 microlitres of the supernatant sample in the step (3) in a sample bottle, analyzing through liquid chromatography or liquid chromatography-tandem mass spectrometry, and simultaneously quantitatively detecting the contents of the vitamin A (retinol) and the vitamin E (alpha-tocopherol) in the blood. The method of simultaneously detecting the contents of the vitamin A (retinol) and the vitamin E (alpha-tocopherol) in the blood is strong in specificity, high in accuracy and sensitivity and short in analysis time.

Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and / or prevention of age-related macular degeneration and / or dystrophies.

Compounds that reduce serum retinol levels are used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods, compounds, and compositions to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions.

Methods of producing a controlled release formulation for an active substance are disclosed, wherein the methods involve dispersing a discontinuous phase comprising an active substance into a continuous phase so as to form a two-phase liquid system comprising droplets of said discontinuous phase, and allowing nanoparticles provided to the two-phase liquid system to congregate at the phase interface to thereby coat the surface of the droplets in at least one layer of said nanoparticles. The methods utilise a concentration of a suitable electrolyte which enhances the nanoparticle congregation such that the coating of nanoparticles on the surface of the droplets presents a semi-permeable barrier to the active substance, or otherwise utilise a amount of the active substance that is greater than the solubility limit of that active substance in the discontinous phase. Formulations comprising vitamin A (retinol) as the active substance for dermal delivery are specifically exemplified.

The present invention discloses one kind of retinol conjugated protein and its preparation process and specific antibody. The present invention expresses retinol conjugated protein effectively for the first time, and the expressed retinol conjugated protein has property near to that of natural retinol conjugated protein (RBP4). Immunizing animal with the expressed retinol conjugated protein can obtain antibody capable of recognizing natural retinol conjugated protein in human body sensitively. The present invention fills in a gap in RBP4 antiserum.

Disclosed are methods for treating hyperpigmentation of skin employing topical application of compositions which comprise at least one peptide manganese complex. Also disclosed are methods wherein the composition further comprises retinol, at least one retinol derivative, or a mixture thereof and methods wherein the composition further comprises active agents selected from active drug substances, emollients, sunscreen agents, skin lightening agents, skin protectants, skin conditioning agents, humectants, and mixtures thereof.

The invention provides a test kit for measuring the content of retinol conjugated protein in serum of a human body and a preparation method of the test kit. The volume ratio of a reagent R1 and a reagent R2 is 3:1. The R1 comprises 0.01-4%w / w of emulsifiers, 0.1-2%w / w of sodium chloride, 0.05-2%w / w of sensitizers, 0.02%w / w of preservative and 30-100mmol / L of buffer solutions. The R2 comprises 0.1-0.5%w / w of latex particle combined with a retinol conjugated protein antibody, 0.1-1.0%w / w of bovine serum albumin, 0.02-2%w / w of Tween 20, 0.02-2%w / w of stabilizers 2, 0.02-2%w / w of protein protective agents, 0.02%w / w of preservative and 20-50mmol / L of buffer solutions. The test kit has wide linearity range, high sensitivity and stability and good clinical application prospect.

An anti-aging composition is provided that contains high potency retinol along with anti-irritant properties. In particular, an anti-aging composition includes a base, from about 0.001% to 20.0 vol % retinol, at least one anti-irritant agent, at least one antioxidant, at least one anti-inflammatory agent, and a moisturizing complex. In one non-limiting illustration, the anti-aging composition contains about 1.0 vol % retinol, plantago lanceolata, hypericum perforatum leaf extract, phytosphingosine, leontopodium alpinum extract, glycyrriza glabra root extract, sambucus nigra flower extract, nordihydrognaiaretic acid, oleanolic acid, spiraea ulmaria flower extract, evodia rutaecarpa fruit extract, boswellia serrata extract, and additives.

The invention relates to a detection kit for a retinol binding protein. The interior of a detection kit body comprises reagents R1 and reagents R2, wherein the reagents R1 comprise a buffer solution, polyethylene glycol, sodium azide, sodium ethylene diamine tetracetate and bovine serum albumin; and the reagents R2 comprise a buffer solution, latex grains combined with retinol binding protein monoclonal antibodies, tween-20, sodium azide, sodium ethylene diamine tetracetate and bovine serum albumin. A sample and the reagents are mixed at a certain volume ratio and generate a series of reactions, and then a reactant is placed under a semi / full-automatic biochemical analyzer, and the speed of absorbance change in the position of a main wavelength of 340nm is detected, so that the concentration magnitude of the retinol binding protein is measured and calculated. The detection kit has the advantages of accuracy, stability and convenience.

The present invention relates to a method of evaluating the cancer state of a subject using lecithin:retinol acyl transferase (LRAT) gene promoter methylation status. Methods of analyzing and quantifying LRAT gene promoter methylation level are also disclosed. The present invention also relates to methods of determining the prognosis for s subject having cancer by assessing LRAT mRNA expression and LRAT protein expression. Methods of cancer detection, diagnosis, prognosis, and treatment are also disclosed.

The present invention relates to a method for stabilizing retinol (Vitamin A), an unstable fat-soluble material, to use the same in cosmetics. The present invention provides an anti-inflammatory and skin wrinkle reducing cosmetic composition containing retinol stabilized by nano-emulsification, wherein a retinol polymer nanocapsule formed by capturing retinol with porous polymer particles is nano-emulsified by a mung bean MCT (medium chain triglyceride) extract and lecithin for stabilizing retinol.

The invention provides a synthetic method for beta-carotene. The synthetic method comprises the following steps: preparing an organic phosphine salt from retinol or a derivative thereof; and subjecting the organic phosphine salt to an intermolecular oxidative coupling reaction in an oxygen atmosphere in the presence of a vanadium compound catalyst and a molecular sieve so as to obtain beta-carotene. According to the invention, clean, environment-friendly, economic, easily-available, convenient, safe and oxygen-containing gas is used as an oxidizing agent, so no harm is posed to environment, cost is low, and industrial production is facilitated; a vanadium compound is used as a catalyst, so time for the coupling reaction is greatly reduced; the molecular sieve is used as a cocatalyst, so the usage amount of the catalyst is lowered, catalytic oxidation effect is improved, and discharge of waste water containing metal ions is reduced; the addition of a polyether phase-transfer catalyst can initiate a reaction of substrates in a heterogeneous-phase reaction system; and a solid alkaline compound forms a complex with the polyether phase-transfer catalyst, and is thus dissolved in an organic phase and participates in the reaction, so the solubility of alkali in the organic phase is effectively controlled, the reaction is promoted, production of by-products is inhibited at the same time, the yield of the target product is increased, and thus, the purpose of improving yield is achieved.

The present invention provides a skin cream which can be used by most individuals on a daily basis to improve the quality of skin tone. The skin cream of the present invention comprises at least one anti-oxidant, an anti-inflammatory agent, an exfoliant, and an agent to protect against UV irradiation. In addition, the skin cream of the present invention may comprise oils, creams, and / or other compounds to promote adsorption of the active ingredients and to increase vibrancy of the skin tone. For example, in an embodiment, the skin cream of the present invention comprises: (a) dimethylaminoethanol (DMAE), (b) α-lipoic acid, (c) lactic acid, (d) retinol, (e) zinc or titanium oxide, and (f) vitamin C, wherein components (a), (b), (c), (d), (e) and (f) are in amounts such that application of the cream to an individual increases the thickness of collagen bundles in the individual's skin.

A group of new compounds, N-(all-trans-Retinoyl)-L-cysteic acid, N-(13-cis-Retinoyl)-L-cysteic acid, N-(all-trans-Retinoyl)-L-cysteinesulfinic acid, N-(13-cis-Retinoyl)-L-cysteinesulfinic acid, N-(all-trans-Retinoyl)-L-homocysteic acid, N-(13-cis-Retinoyl)-L-homocysteic acid, and sodium salts of these compounds, including sodium salts of their esters and amides, is shown to exhibit therapeutic effects per se, and which compounds in combination with cytotoxic compounds, such as docetaxel, paclitaxel, doxorubicin and mitoxantrone, exhibit a synergistic effect. These compounds make it possible to manufacture new formulations of poorly soluble pharmaceutical compounds, and the present invention discloses a process of manufacturing water-soluble formulations of such compounds, exemplified by docetaxel, and paclitaxel, exhibiting enhanced pharmacological activity, and formulations of water-soluble pharmaceuticals exemplified by doxorubicin and mitoxantrone, exhibiting improved therapeutic efficacy.

The invention relates to a skin compactness composition which comprises hyaluronic acid, hydrolyzed collagen, dipalmitoyl hydroxyproline, compound amino acid, decarboxylation peptide, acetyl hexapeptide, plankton extracts, lactic acid bacillus / soybean milk fermentation product filtrate, dipotassium glycyrrhizinate, retinyl palmitate, VE and hydrolyzed sesame protein. By the aid of anti-aging vitamin, amino acid, derivatives and peptides, an extracellular matrix structure matrix is endogenously improved, the dipalmitoyl hydroxyproline, palmityl glycine, the decarboxylation peptide, the acetyl hexapeptide, sodium hyaluronate, retinol, the hydrolyzed collagen, the plankton extracts, the lactic acid bacillus / soybean milk fermentation product filtrate and the dipotassium glycyrrhizinate serve as main components, thin wrinkles caused by skin laxity are comprehensively repaired, metalloprotease activity is inhibited by promoting collagen and elastin synthesis, skin compactness and elasticity are improved, and young skins are restored.